Key Finding:
Increased HER2 positivity was detected via CISH testing compared to IHC and NGS, which may reflect the heterogeneity of HER2 amplification due to mixed histology between the sarcoma and carcinoma portion of the tumor.
Publications
HER2 in uterine carcinosarcoma: testing platforms and implications for targeted therapy
– Caris Life Sciences
Download Publication